BioSig Enters into Groundbreaking Merger with Streamex
Deal News | May 05, 2025 | Globenewswire
BioSig Technologies, Inc., a medical technology company listed on NASDAQ under the ticker BSGM, has announced its entry into a Letter of Intent to merge with Streamex Exchange Corporation. This proposed all-stock transaction aims to leverage significant growth potential, enhance market reach, and create new opportunities for both entities. The merger entails significant board and management changes, with Streamex Co-Founder and CEO Henry McPhie set to assume the role of Chief Executive Officer of the combined entity. Additionally, Streamex Co-Founder Morgan Lekstrom will join as Chairman of the Board. Strategic advisors like Frank Giustra, Mathew August, and Mitchell Williams are set to bolster the company's commodity and market strategies. Under the merger's terms, current BioSig shareholders will own a significant portion, while former Streamex stockholders will gain a 75% stake post-preferred stock conversion. The statement includes forward-looking guidance, cautionary notes regarding business risks, and emphasizes that actual results may vary.
Sectors
- Medical Technology
- Financial Services
- Corporate Finance
Geography
- United States – BioSig Technologies is based in the United States and the press release originates from Los Angeles, indicating significant U.S. market involvement.
Industry
- Medical Technology – BioSig Technologies operates within the medical technology sector, focusing on innovations that improve healthcare delivery and patient outcomes.
- Financial Services – Streamex Exchange operates within the financial services industry, likely offering platforms or services related to trading or financial exchanges.
- Corporate Finance – The merger involves strategic financial structuring such as stock ownership and management changes, which are central concerns of corporate finance.
Financials
- 19.9% – Initial ownership of Streamex stockholders of the outstanding Common Stock of the combined company.
- 75% – Ownership stake of Streamex stockholders in the outstanding Common Stock after conversion of Preferred Stock post-merger.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| BioSig Technologies, Inc. | Target | Company | A NASDAQ-listed medical technology company involved in the merger. |
| Streamex Exchange Corporation | Bidding Company | Company | The company entering into a merger with BioSig Technologies. |
| Anthony Amato | CEO and Chairman of BioSig | People | Current CEO and Chairman of BioSig Technologies, involved in the merger announcement. |
| Henry McPhie | New CEO of Combined Entity | People | Co-Founder and CEO of Streamex, set to become CEO post-merger. |
| Morgan Lekstrom | New Chairman | People | Co-Founder and Chairman of Streamex, set to join as Chairman of the combined entity. |
| Frank Giustra | Strategic Investor and Advisor | People | Prominent entrepreneur joining as a Strategic Advisor on commodities post-merger. |
| Mathew August | Strategic Advisor | People | Advisor on US Capital Markets with experience in diverse industries. |
| Mitchell Williams | Strategic Advisor | People | Advisor on US Capital Markets, with extensive experience in investment management. |